Drug Holidays in the Treatment With Alendronate in Postmenopausal Women With Osteoporosis

This study has been completed.
Sponsor:
Information provided by:
Ciudad Universitaria, Spain
ClinicalTrials.gov Identifier:
NCT00936260
First received: July 9, 2009
Last updated: NA
Last verified: January 1998
History: No changes posted
  Purpose

The purpose of this study is to determine the duration of the treatment with alendronate in postmenopausal women with osteoporosis.


Condition Intervention
Osteoporosis
Drug: alendronate

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Drug Holidays in the Treatment With Alendronate in Postmenopausal Women With Osteoporosis

Resource links provided by NLM:


Further study details as provided by Ciudad Universitaria, Spain:

Primary Outcome Measures:
  • Bone mineral density [ Time Frame: Every year ] [ Designated as safety issue: Yes ]

Secondary Outcome Measures:
  • Fractures [ Time Frame: Every year ] [ Designated as safety issue: No ]

Enrollment: 228
Study Start Date: January 1998
Study Completion Date: December 2004
Primary Completion Date: December 2004 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: alendronate 6 years Drug: alendronate
several duration of treatment
Other Name: fosamax
Experimental: alendronate 5 years
No treatment during year 6th
Drug: alendronate
several duration of treatment
Other Name: fosamax
Experimental: alendronate 5 years, not continued
No treatment during year 5th
Drug: alendronate
several duration of treatment
Other Name: fosamax
Experimental: alendronate 4 years
No treatment during year 5th and 6th
Drug: alendronate
several duration of treatment
Other Name: fosamax
Experimental: alendronate 5 years, uncontinued
No treatment during year 4th
Drug: alendronate
several duration of treatment
Other Name: fosamax
Experimental: alendronate 4 years, not continued
No treatment during year 4th and 6th
Drug: alendronate
several duration of treatment
Other Name: fosamax
Experimental: alendronate 4 years, uncontinued
No treatment during year 4th and 5th
Drug: alendronate
several duration of treatment
Other Name: fosamax
Experimental: Alendronato 3 years
No treatment during the last 3 years
Drug: alendronate
several duration of treatment
Other Name: fosamax

Detailed Description:

The duration of the treatment with alendronate is not well established. The investigators recruited 228 women with postmenopausal osteoporosis. They all received alendronate during the first 3 years of monitoring and were later on randomized to whether different regimens of intermittent treatment or to carry on 3 years more.

  Eligibility

Genders Eligible for Study:   Female
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • postmenopausal osteoporosis under densitometric criteria of the World Health Organization

Exclusion Criteria:

  • secondary osteoporosis
  • alteration in analytic parameters (total proteins, calcium, phosphorus, vitamin D, parathyroid hormone, thyroid hormone, transaminase, creatinine)
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00936260

Locations
Spain
University San Carlos Hospital
Madrid, Spain, 28040
Sponsors and Collaborators
Ciudad Universitaria, Spain
Investigators
Study Director: Carlos Lozano Tonkin, doctor university san carlos hospital
  More Information

No publications provided

Responsible Party: Esther Alvarez-Rodriguez, University San Carlos Hospital
ClinicalTrials.gov Identifier: NCT00936260     History of Changes
Other Study ID Numbers: individual reseacher
Study First Received: July 9, 2009
Last Updated: July 9, 2009
Health Authority: Spain: Comité Ético de Investigación Clínica

Keywords provided by Ciudad Universitaria, Spain:
osteoporosis
postmenopausal
alendronate

Additional relevant MeSH terms:
Osteoporosis
Bone Diseases, Metabolic
Bone Diseases
Musculoskeletal Diseases
Alendronate
Bone Density Conservation Agents
Physiological Effects of Drugs
Pharmacologic Actions

ClinicalTrials.gov processed this record on August 01, 2014